Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Definitions

• the present invention relates to a capsule dosage form comprising donepezil or a pharmaceutically acceptable salt thereof in combination with memantine or a pharmaceutically acceptable salt thereof.
• Acetylcholinesterase inhibitors are drugs that inhibit the acetylcholinesterase enzyme from breaking down acetylcholine, thereby increasing both the level and duration of action of the neurotransmitter acetylcholine.
• Acetylcholinesterase inhibitors are classified as reversible, irreversible, or pseudo-irreversible.
• Donepezil acts as a centrally acting reversible acetylcholinesterase inhibitor. It binds and inactivates reversibly the cholinesterases, thus inhibiting hydrolysis of acetylcholine. This results in increased acetylcholine concentrations at cholinergic synapses.
• Donepezil marketed under the trade name Aricept®, is a medication used in the palliative treatment of Alzheimer's disease. It is used to improve cognition and behavior of people with Alzheimer's, but does not slow the progression of or cure the disease.
• the N-methyl-D-aspartate receptor (also known as the NMDA receptor or NMDAR), is a glutamate receptor and ion channel protein found in nerve cells. It is activated when glutamate and glycine (or D-serine) bind to it, and when activated it allows positively charged ions to flow through the cell membrane.
• the NMDA receptor is very important for controlling synaptic plasticity and memory function.
• Memantine is a NMDAR antagonist.
• NMDA receptor antagonists are a class of anesthetics that work to antagonize, or inhibit the action of, the NMDAR.
• Memantine is the first in a novel class of Alzheimer's disease medications acting on the glutamatergic system by blocking NMDA receptors.
• Memantine has been shown to have a modest effect in moderate-to-severe Alzheimer's disease and in dementia with Lewy bodies. It is marketed under the brand Namenda® among others, its chemical name is 3,5-dimethyladamantan-1-amine and its chemical structure is shown in the Formula 2.
• patent document numbered EP1509232B1 discloses the use of a composition comprising acetylcholinesterase inhibitor(s) and NMDA-antagonist(s) to treat mild cognitive impairment or dementia in connection with moderate to severe Alzheimer's.
• acetylcholinesterase inhibitor(s) and NMDA-antagonist(s) to treat mild cognitive impairment or dementia in connection with moderate to severe Alzheimer's.
• donepezil and the use of memantine as active agents are also stated in this patent document.
• active agents In order to combine two or more different active agents in one dosage form, active agents should be compatible or they should be adjusted to be compatible with each other to achieve desired stability and dissolution profile.
• a dosage form especially a capsule formulation with mini tablets, comprising a combination of donepezil and memantine which ensures the required dissolution profiles and accordingly safe and efficient plasma levels of both active agents to provide a high patient compliance, bioavailability and stability.
• the main object of the present invention is to obtain combination formulations comprising donepezil and memantine eliminating all aforesaid problems and bringing additional advantages to the relevant prior art.
• Another object of the present invention is to obtain combination formulations of donepezil and memantine with high stability, bioavalibility and patient compliance.
• a further object of the present invention is to develop combination formulations of donepezil and memantine having an improved level of dissolution rate and solubility.
• Another object of the present invention is to provide an immediate release capsule form comprising donepezil and memantine.
• a further object of the present invention is to provide a capsule dosage form comprising donepezil and memantine preferably in separate mini tablets.
• Yet another object of the present invention is to apply different coatings on donepezil mini tablet(s) and memantine mini tablet(s), which exhibit different solubilities in water, to obtain adequate dissolution profiles from each of them.
• the present invention relates to solid oral pharmaceutical compositions comprising donepezil or a pharmaceutically acceptable salt thereof in combination with memantine or a pharmaceutically acceptable salt thereof as active agents and at least one pharmaceutically acceptable excipient.
• the active agents are donepezil hydrochloride (donepezil HCl) and memantine hydrochloride (memantine HCl).
• the amount of donepezil HCl is between 1-30% by weight of the total composition. Preferably this amount is between 1-20% by weight of the total composition. More preferably donepezil HCl is present between 2-10% by weight in the total composition.
• the amount of memantine HCl is between 1-40% by weight of the total composition. Preferably this amount is between 3-30% by weight of the total composition. More preferably memantine HCl is present between 5-15% by weight in the total composition.
• donepezil HCl is present in an amount of 1 to 50 mg, more preferably 5 to 10 mg in the total composition.
• memantine HCl is present in an amount of 1 to 50 mg, more preferably 5 to 20 mg in the total composition.
• the ratio of donepezil HCl to memantine HCl is in the range of 1:0.5 to 1:8 and preferably 1:1 to 1:4. The most preferred ratios are 1:1, 1:2, 1:3 and 1:4.
• the composition is in the form of coated tablet, trilayer tablet, bilayer tablet, multilayer tablet, orally disintegrating tablet, mini tablet, pellet, sugar pellet, buccal tablet, sublingual tablet, effervescent tablet, immediate release tablet, modified release tablet, film-coated tablet, gastric disintegrating tablet, pill, capsule, oral granule, powder, coated bead system, microsphere, tablet in tablet, inlay tablet, dragee, sachet or orally administrable film.
• the dosage form of the composition is preferably an immediate release capsule.
• the capsule is made of hydroxypropyl methylcellulose (HPMC) or gelatin.
• donepezil HCl is present in a dosage form such as tablet, coated tablet, mini tablet, coated mini tablet, coated bead system, powder, pellet or a mixture thereof.
• memantine HCl is present in a dosage form such as tablet, coated tablet, mini tablet, coated mini tablet, coated bead system or a mixture thereof.
• the capsule dosage form subjected to the invention is filled with at least one dosage form of donepezil HCl mini and at least one dosage form of memantine HCl.
• the capsule dosage form subjected to the invention is filled with at least one donepezil HCl mini tablet and at least one memantine HCl mini tablet.
• mini tablet refers to a small tablet, comprising the active agent, with a diameter equal to or less than 4 mm and a thickness equal to or less than 3 mm.
• the mini tablets have round shape and smooth surface to ease coating process.
• the capsule form filled with mini tablets has many advantages as the simplicity of dosage adjustement, the chance of composing alternative dosage combinations using one or more equivalent mini tablets together, the opportunity to select excipients separately for each mini tablet, to perform different film coatings which are favorable for each mini tablets having different solubility and accordingly to provide the homogeneous distribution of active agents.
• donepezil HCl mini tablets or memantine HCl mini tablets or both of them are coated with film layer.
• the dosage form of donepezil HCl comprises donepezil HCl and at least one pharmaceutically acceptable excipient selected from diluents, binders, disintegrants, lubricants, or mixtures thereof.
• the ratio of donepezil HCl is between 1-30%, preferably 5-20% and more preferably 10% by weight of the dosage form of donepezil HCl.
• the dosage form of donepezil HCl comprises donepezil HCl in an amount of 1 to 10 mg and more preferably 2,5 mg.
• the dosage form of memantine HCl comprises memantine HCl and at least one pharmaceutically acceptable excipient selected from diluents, lubricants, glidants or mixtures thereof.
• the dosage form of memantine HCl is free of disintegrant to provide a homogenous dissolution along the dissolution of the dosage form of donepezil HCl, since memantine HCl already has high solubility and rapid disintegration potential.
• the ratio of memantine HCl is between 1-40%, preferably 10-30% and more preferably 20% by weight of the dosage form of memantine HCl.
• the dosage form of memantine HCl comprises memantine HCl in an amount of 1 to 20 mg and more preferably 5 mg.
• the dosage form of donepezil HCl comprises at least one diluent which is selected from the group comprising lactose monohydrate, corn starch, lactose, dibasic calcium phosphate, microcrystalline cellulose, mannitol, spray-dried mannitol, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
• diluent which is selected from the group comprising lactose monohydrate, corn starch, lactose, dibasic calcium phosphate, microcrystalline cellulose, mannitol, spray-dried mannitol, de
• the dosage form of donepezil HCl comprises two diluents which are lactose monohydrate and corn starch.
• the amount of lactose monohydrate is between 10-90%, preferably 30-80% and more preferably 50-70% by weight of the dosage form of donepezil HCl.
• the amount of corn starch is between 1-50%, preferably 5-30% and more preferably 10-20% by weight of the dosage form of donepezil HCl.
• the dosage form of donepezil HCl comprises at least one disintegrant which is selected from the group comprising microcrystalline cellulose, croscarmellose sodium, sodium carbonate, hydroxylpropyl cellulose (HPC), cross-linked polyvinylpyrrolidone (crospovidon), copovidon, polycarbophil, low-substitue poloxamer, alginic acid and alginates, ion-exchange resins, magnesium aluminum silica, sodium dodecyl sulphate, sodium carboxy methyl cellulose, carboxy methyl cellulose calcium, docusate sodium, guar gum, polyacrylin potasium, sodium alginate, sodium glysin carbonate, sodium lauryl sulphate or mixtures thereof.
• disintegrant which is selected from the group comprising microcrystalline cellulose, croscarmellose sodium, sodium carbonate, hydroxylpropyl cellulose (HPC), cross-linked polyvinylpyrrolidone (crospovidon), copovi
• the dosage form of donepezil HCl comprises one disintegrant which is microcrystalline cellulose.
• the amount of microcrystalline cellulose is between 1-30%, preferably 5-15% by weight of the dosage form of donepezil HCl.
• the dosage form of donepezil HCl comprises at least one binder which is selected from the group comprising copovidone, copolyvidone, polyvinylpyrrolidone (PVP, povidone), povidone K30, carnauba wax, hydroxypropyl methyl cellulose (hypromellose, HPMC), pullulan, polymethacrylate, glyceryl behenate, hydroxypropyl cellulose (HPC), carboxymethyl cellulose (CMC), methyl cellulose (MC), hydroxyethyl cellulose, sodium carboxymethyl cellulose (Na CMC), ethyl cellulose, microcrystalline cellulose, polymetacrylates, polyethylene oxide, polyvinyl alcohol, polycarbophil, polyvinyl acetate and its copolymers, gelatin, xanthan gum, guar gum, alginate, carrageen, kollagen, agar, pectin, hyaluronic acid, carbomer, cellulose acetate
• the dosage form of donepezil HCl comprises one binder which is hydroxypropyl cellulose.
• the amount of hydroxypropyl cellulose is between 1-10%, preferably 1-5% by weight of the dosage form of donepezil HCl.
• the ratio of the total weight of disintegrant to the total weight of binder is in the range of 1:1 to 10:1, preferably 2:1 to 8:1 and more preferably 4:1 to 6:1, in the dosage form of donepezil HCl. This preferred selection of range assures the desired dissolution and disintegration profiles.
• the dosage form of donepezil HCl comprises comprises at least one lubricant which is selected from the group comprising sodium lauryl sulphate, sodium stearyl fumarate, magnesium stearate, colloidal silicon dioxide, zinc stearate, calcium stearate, mineral oil, talc, polyethylene glycol, glyceryl monostearate, glyceryl palmitostearate, magnesium lauryl sulphate, fumaric acid, zinc stearate, stearic acid, hydrogenated natural oils, silica, paraffin or mixtures thereof.
• lubricant which is selected from the group comprising sodium lauryl sulphate, sodium stearyl fumarate, magnesium stearate, colloidal silicon dioxide, zinc stearate, calcium stearate, mineral oil, talc, polyethylene glycol, glyceryl monostearate, glyceryl palmitostearate, magnesium lauryl sulphate, fumaric acid, zinc stearate, ste
• the dosage form of donepezil HCl comprises one lubricant which is magnesium stearate.
• the amount of magnesium stearate is between 0.1-5%, preferably 0.2-1% by weight of the dosage form of donepezil HCl.
• the dosage form of donepezil HCl is donepezil HCl mini tablet or donepezil HCl powder.
• the dosage form of donepezil HCl is donepezil HCl mini tablet.
• the donepezil HCl mini tablet preferably comprises at least one coating layer to protect the composition against the moisture and maintain the stability.
• Suitable coating ingredients are selected from the group comprising hydroxypropylmethyl cellulose (hypromellose), lactose monohydrate, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat IR), ethylcellulose dispersions (Surelease), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA) and all kinds of OpadryTM, pigments, dyes, titanium dioxide, iron oxide or polymethylmetacrylate copolymers and mixtures thereof.
• the donepezil HCl mini tablet has a hydroxypropyl methylcellulose based coating layer (Opadry) comprising lactose monohydrate, hydroxypropylmethyl cellulose (hypromellose), titanium dioxide, polyethylene glycol (PEG) and optionally one ore more pigment.
• Opadry hydroxypropyl methylcellulose based coating layer
• lactose monohydrate hydroxypropylmethyl cellulose (hypromellose)
• titanium dioxide hydroxypropylmethyl cellulose (hypromellose)
• PEG polyethylene glycol
• optionally one ore more pigment optionally one ore more pigment.
• the dosage form of memantine HCl comprises at least one diluent which is selected from the group comprising lactose monohydrate, corn starch, lactose, dibasic calcium phosphate, microcrystalline cellulose, mannitol, spray-dried mannitol, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
• diluent which is selected from the group comprising lactose monohydrate, corn starch, lactose, dibasic calcium phosphate, microcrystalline cellulose, mannitol, spray-dried mannitol, dex
• the dosage form of memantine HCl comprises two diluents which are microcrystalline cellulose and lactose monohydrate.
• the amount of microcrystalline cellulose is between 10-80%, preferably 20-70% and more preferably 35-55% by weight of the dosage form of memantine HCl.
• the amount of lactose monohydrate is between 10-60%, preferably 20-50% and more preferably 30-40% by weight of the dosage form of memantine HCl.
• the dosage form of memantine HCl comprises at least one lubricant and at least one glidant which are selected from the group comprising sodium lauryl sulphate, sodium stearyl fumarate, magnesium stearate, colloidal silicon dioxide, zinc stearate, calcium stearate, mineral oil, talc, polyethylene glycol, glyceryl monostearate, glyceryl palmitostearate, magnesium lauryl sulphate, fumaric acid, zinc stearate, stearic acid, hydrogenated natural oils, silica, paraffin or mixtures thereof.
• the dosage form of memantine HCl comprises two lubricants which are magnesium stearate and talc.
• the amount of magnesium stearate is between 0.1-5%, preferably 0.5-2% by weight of the dosage form of memantine HCl.
• the amount of talc is between 0.1-5%, preferably 0.5-2% by weight of the dosage form of memantine HCl.
• the dosage form of memantine HCl comprises one glidant which is colloidal silicon dioxide.
• the amount of colloidal silicon dioxide is between 0.05-1%, preferably 0.1-0.5% by weight of the dosage form of memantine HCl.
• the ratio of the total weight of lubricant to the total weight of glidant is in the range of 20:1 to 1:1, preferably 15:1 to 5:1 and more preferably 12:1 to 8:1, in the dosage form of memantine HCl. This preferred selection of range assures the desired dissolution and disintegration profiles.
• the dosage form of memantine HCl is memantine HCl mini tablet.
• the memantine HCl mini tablet preferably comprises at least one coating layer providing extended release to adjust the disintegration rate and distribution of memantine HCl and maintain the homogeneous dissolution.
• Suitable coating ingredients are selected from the group comprising hydroxypropylmethyl cellulose (hypromellose), lactose monohydrate, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat IR), methacrylic acid - ethyl acrylate copolymer (Kollicoat MAE), polysorbate 80, sodium lauryl sulphate, simethicone emulsions, triacetine, ethylcellulose dispersions (Surelease), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA) and all kinds of OpadryTM, pigments, dyes, titanium dioxide, iron oxide
• the memantine HCl mini tablet has a methacrylic acid based coating layer to protect the gastric mucosa from the memantine HCl which is an aggressive active agent.
• the methacrylic acid based coating comprising methacrylic acid - ethyl acrylate copolymer (1:1 by weight), polysorbate 80, sodium lauryl sulphate, simethicone emulsion and triacetine.
• capsule forms containing mini tablets have been developed and desired dissolution rates and stability have been achieved.
• the solid oral pharmaceutical composition is in the form of a capsule comprising two donepezil HCl mini tablets and one memantine HCl mini tablet.
• the solid oral pharmaceutical composition is in the form of a capsule comprising two donepezil HCl mini tablets and two memantine HCl mini tablets.
• the solid oral pharmaceutical composition is in the form of a capsule comprising two donepezil HCl mini tablets and three memantine HCl mini tablets.
• the solid oral pharmaceutical composition is in the form of a capsule comprising two donepezil HCl mini tablets and four memantine HCl mini tablets.
• the solid oral pharmaceutical composition is in the form of a capsule comprising four donepezil HCl mini tablets and four memantine HCl mini tablets.
• capsule dosage form comprising donepezil HCl powder and memantine HCl mini tablet, is comprised of;
• capsule dosage form comprising donepezil HCl mini tablet and memantine HCl mini tablet, is comprised of;
• the below given formulations can be used in the solid oral pharmaceutical composition subjected to the invention. These examples are not limiting the scope of the present invention and should be considered under the light of the foregoing detailed disclosure.
• Example 1 Formulations of different dosage forms present in the capsule form
• Example 2 Formulations of mini tablets present in the capsule form

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=60781854

Family Applications (1)

Country Status (3)

Cited By (2)

Citations (4)

• 2016
  • 2016-12-22 TR TR2016/19184A patent/TR201619184A2/tr unknown
• 2017
  • 2017-12-21 EP EP17209510.1A patent/EP3338767A1/en not_active Withdrawn
  • 2017-12-21 WO PCT/EP2017/084130 patent/WO2018115300A1/en active Application Filing

Patent Citations (4)

Also Published As

Similar Documents

Legal Events